title: Specific IgE serum concentration is associated with symptom severity in children with seasonal allergic rhinitis.
abstract: BACKGROUND
  The impact of allergen-specific and total IgE serum levels before and during the pollen season on symptom severity as well as efficacy of treatment with anti-IgE requires further delineation.
  
  
  METHODS
  Birch and grass pollen allergic patients aged 6-17 years with seasonal allergic rhinitis (SAR) were analyzed for the association of IgE serum concentration with symptom severity and rescue medication use (combination: symptom load, SL) during the grass pollen season. Reference group A (n = 53) received placebo, while group B (n = 54) received Omalizumab (anti-IgE) monotherapy before and during the grass pollen season.
  
  
  RESULTS
  Patients on placebo with high baseline specific grass pollen IgE (>50 kU/l) had a significantly higher SL compared with those with low IgE levels (< or =50 kU/l): SL 1.28 vs 0.61, P = 0.015. This association was nonexistent in patients treated with anti-IgE. In contrast, baseline total IgE levels did not correlate with SL in any group. Patients with anti-IgE treatment and high free total IgE levels (>16.7 ng/ml) had a significantly higher SL compared with those with low free total IgE levels (< or =16.7 ng/ml): SL 0.63 vs 0.23, P = 0.031.
  
  
  CONCLUSIONS
  Baseline specific IgE, but not total IgE, is associated with symptom severity during the pollen season in children with SAR. Likewise, the symptom load in SAR patients with anti-IgE correlates with free total IgE levels. Although further research in larger populations is needed to confirm our findings, our data suggest that specific IgE can be used as a parameter for patient selection for this kind of treatment.
authors.affiliation: Pediatric Pneumology and Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Rolinck-Werninghaus
authors.forename: T
authors.initials: T
authors.lastname: Keil
authors.forename: M
authors.initials: M
authors.lastname: Kopp
authors.forename: S
authors.initials: S
authors.lastname: Zielen
authors.forename: U
authors.initials: U
authors.lastname: Schauer
authors.forename: A
authors.initials: A
authors.lastname: von Berg
authors.forename: U
authors.initials: U
authors.lastname: Wahn
authors.forename: E
authors.initials: E
authors.lastname: Hamelmann
mesh_terms: D000293:Adolescent; D018926:Anti-Allergic Agents / Q000494:pharmacology; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D006801:Humans; D007073:Immunoglobulin E / Q000009:adverse effects / Q000096:biosynthesis / Q000097:blood*; D000069444:Omalizumab; D006255:Rhinitis, Allergic, Seasonal / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology*; D012720:Severity of Illness Index
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E